AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03400527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
Study NCT02133430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index, as measured by a BIS processor
Description: Comparisons of incidence of postoperative delirium.
Study NCT05438277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPA)
Description: injection into subacromial or glenohumeral space with MPA
Study NCT05438277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide (TA)
Description: injection into subacromial or glenohumeral space with TA
Study NCT03428100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03428100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT03428100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03428100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care.
Study NCT03428100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid
Description: Administered as standard-of-care.
Study NCT04564911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring and Education
Description: Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
Study NCT04564911 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capillary glucose monitoring and Education
Description: Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
Study NCT02979821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib
Description: A cycle of study treatment is defined as 28 days.
Study NCT01047280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarinol G-80 ® treatment
Description: dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
Study NCT01047280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower oil
Description: 3.5 g/d of safflower oil
Study NCT01047280 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G-c9, t11
Description: 3.5 g/day of c9, t11 CLA
Study NCT04936503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Resting electrocardiogram
Description: An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
Study NCT04936503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress test
Description: In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
Study NCT04936503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac echocardiography
Description: In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
Study NCT04936503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac rhythm monitoring
Description: In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
Study NCT04936503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: To determine the rhythmic risk of athletes
Study NCT04936503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injected Cardiac MRI
Description: High resolution MRIs is performed on 200 athletes :~* 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~* 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)
Study NCT04936503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for biobank
Description: For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers).
Study NCT02895204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6g of maltodextrin
Study NCT01124383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
Study NCT01124383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with sedation
Description: For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score \< 4.
Study NCT03683992 — intervention group
Intervention type: DEVICE
Intervention: Triathlon total knee system
Description: Implantable
Study NCT01115127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: 30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
Study NCT01115127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol
Description: 30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
Study NCT01115127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin plus myo-inositol
Description: 30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
Study NCT02260713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow cell
Description: Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
Study NCT00082875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study NCT00082875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00082875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02120001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT cleaning maneuver
Description: EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period.
Study NCT03969680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Auotologous BMSCs plus autologous PRP
Description: 30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
Study NCT03969680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Auotologous PRP
Description: 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
Study NCT04606186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)
Description: Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
Study NCT04606186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-lozenges (BioGaia)
Description: Placebo-lozenges (BioGaia)
Study NCT00777738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BORTEZOMIB
Description: * Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~* For responding patients : up to 6 cycles~* For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days
Study NCT05033249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte count
Description: Automatically calculated immature granulocyte count in white blood cell count
Study NCT05033249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immature granulocyte percentage
Description: Automatically calculated immature granulocyte percentage in white blood cell count
Study NCT02872805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEPFAR Enhanced Standard of Care (PESCA)
Description: Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
Study NCT02872805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Transition Advocate (PTA)
Description: The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Description: Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium
Description: Anesthesia induction:midazolam (0.03\~0.05 mg/kg), sufentanil(0. 5\~0.8 μg/kg), etomidate ( 0.2\~0.6mg/kg) and rocuronium(0.6mg/kg)
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
Study NCT04663412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)
Description: Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
Study NCT00770705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Description: The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Continuous pump infusion normal saline with identical volume of dexmedetomidine.
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
Study NCT02134093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance of anesthesia , propofol, remifentanil,vecuronium
Description: Continuous infusion of propofol （3\~6 mg/kg/h）, remifentanil （0.05\~0.3 μg/kg/min）is required to maintain Entropy within 40\~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05\~0.1mg/kg） as needed to maintain muscle relaxation.
Study NCT01877200 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study NCT01845779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCF regimen
Study NCT04361084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional simulated training
Description: traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
Study NCT04361084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed reality simulation
Description: using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
Study NCT01439113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided IV placement
Description: The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
Study NCT03003234 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Duodenogastroscopy
Description: Catheter goes through the mouth in the duodenum to take duodenal biopsies.
Study NCT03003234 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Duodenal aspiration catheter
Description: Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
Study NCT03003234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutri drink
Description: Liquid meal of 200 ml.
Study NCT02605759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoBalloon Focal Ablation System
Description: Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
Study NCT00750763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colonlytely
Description: Bowel preparation
Study NCT00750763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picolax/Picoprep
Description: Bowel preparation
Study NCT00750763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Bowel preparation
Study NCT01983215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena vac
Study NCT00698815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00698815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT00698815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT00555074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Tungstate
Description: Sodium Tungstate, 200 mg BID, oral route during 6 weeks
Study NCT00555074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, BID, oral route during 6 weeks
Study NCT04726735 — intervention group
Intervention type: BIOLOGICAL
Intervention: Samples of bladder tissue
Description: Samples of bladder tissue collected between 2007 and 2011.
Study NCT04197271 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency Hernia Repair
Description: Emergency repair of hernia using method selected by treating surgeon.
Study NCT04197271 — intervention group
Intervention type: OTHER
Intervention: Conservative management
Description: Treatment of hernia without resort to surgery
Study NCT03901846 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ColdZyme
Description: ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
Study NCT02307227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT02307227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02307227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT02307227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03490617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal misoprostol
Description: To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
Study NCT03490617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women